JPH07242539A - Composition having laxative effect - Google Patents

Composition having laxative effect

Info

Publication number
JPH07242539A
JPH07242539A JP5440994A JP5440994A JPH07242539A JP H07242539 A JPH07242539 A JP H07242539A JP 5440994 A JP5440994 A JP 5440994A JP 5440994 A JP5440994 A JP 5440994A JP H07242539 A JPH07242539 A JP H07242539A
Authority
JP
Japan
Prior art keywords
composition
case
laxative effect
laxative
sugar alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5440994A
Other languages
Japanese (ja)
Other versions
JP3850891B2 (en
Inventor
Katsuhiro Fukahori
勝博 深堀
Hiroaki Takahashi
洋明 高橋
Hidetomo Sakurai
英知 櫻井
Yoshikimi Kaneko
由公 金子
Kazuaki Kato
和昭 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Towa Chemical Industry Co Ltd
Zeria Pharmaceutical Co Ltd
Original Assignee
Towa Chemical Industry Co Ltd
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Towa Chemical Industry Co Ltd, Zeria Pharmaceutical Co Ltd filed Critical Towa Chemical Industry Co Ltd
Priority to JP5440994A priority Critical patent/JP3850891B2/en
Publication of JPH07242539A publication Critical patent/JPH07242539A/en
Application granted granted Critical
Publication of JP3850891B2 publication Critical patent/JP3850891B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

(57)【要約】 【構成】 有機酸と、それぞれ単独では緩下作用を持た
ない量の糖アルコール及びカルシウム塩を含有する。 【効果】 安全で且つ摂取または服用時の感じが良好
で、飲食品として摂取できる自然さを持ちながら不快な
症状を伴わない緩下効果を有する組成物であり、糖アル
コールや他の成分をそれぞれ単独で用いた場合よりも少
ない量で相乗的な緩下効果を持ち、且つ、安全性が高
く、しかも、腹部膨満感、放屁、グル音等の糖アルコー
ルを用いた場合に見られる不快な症状がほとんど無いこ
とから、排便促進効果や緩下効果を有する組成物として
極めて有効で、糖尿病患者にも悪影響が出にくいという
特徴も備えており、従来品よりも幅広い対象者に使用す
ることができる。
(57) [Summary] [Structure] An organic acid and an amount of sugar alcohol and calcium salt that do not have a laxative effect by themselves are contained. [Effect] It is a composition that is safe and has a good feeling when ingested or taken, and has a laxative effect that does not cause any unpleasant symptom while having naturalness so that it can be ingested as a food or drink. It has a synergistic laxative effect with a smaller amount than when used alone, and is highly safe, and moreover, it is an unpleasant symptom that is observed when sugar alcohol such as abdominal bloating, flatus, and guru is used. Since it has almost no urine, it is extremely effective as a composition having a defecation-promoting effect and laxative effect, and also has the characteristic that it does not easily cause adverse effects on diabetic patients, and can be used for a wider range of subjects than conventional products. .

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】[Industrial applications]

【0002】本発明は緩下効果を有する組成物に関する
ものであり、さらに詳しくは、摂取または服用に際して
制約が少なく、安全で、摂取または服用後も腹痛や腹部
膨満感等の種々の不快な症状を呈することのない緩下効
果を有する組成物に関するものである。
The present invention relates to a composition having a laxative effect, and more specifically, it is safe with few restrictions when ingested or taken, and various unpleasant symptoms such as abdominal pain or bloating after ingestion or administration are safe. The present invention relates to a composition having a laxative effect which does not exhibit

【0003】[0003]

【従来の技術】[Prior art]

【0004】便秘は生活様式、食事、運動、排便習慣お
よび心理的影響等の原因により生じ、乾燥した硬い小さ
な糞塊を排泄したり排便回数が減少する症状である。
[0004] Constipation is a symptom caused by lifestyle, diet, exercise, defecation habits, psychological influences, etc., and excretes dry and hard small fecal masses or the frequency of defecation.

【0005】便秘は、女性に多く見られるような、大腸
の神経興奮性低下により腸管が弛緩し、腸内容物が停滞
し水分吸収が進み、便が硬くなり上行結腸と直腸に便が
滞留し腹部が膨満する弛緩性便秘を初めとして、痙攣性
便秘、直腸性便秘のような機能性便秘と手術後の癒着に
よる狭窄等の原因で生じる器質性便秘、鎮咳剤等の腸管
運動の抑制により生じる薬物性便秘等に分けられる。
Constipation, which is often seen in women, is caused by a decrease in nerve excitability of the large intestine, resulting in relaxation of the intestinal tract, stagnation of intestinal contents and increased water absorption, stiffening of stool, and retention of stool in the ascending colon and rectum. Drugs caused by functional constipation such as spasmodic constipation, rectal constipation and functional constipation such as rectal constipation and stenosis due to adhesion after surgery, and suppression of intestinal motility such as antitussives. Divided into sexual constipation.

【0006】これらのような便秘の症状を軽減するため
に従来から用いられている下剤または緩下効果を有する
物質には、大腸刺激性のアントラキノン系生薬下剤、
小腸刺激性のヒマシ油、カルボキシメチルセルロー
スを初めとする膨張性下剤、硫酸マグネシウムを初め
とする塩類下剤、糖アルコール等の糖類下剤がある。
[0006] The laxatives or substances having a laxative effect that have been conventionally used to reduce the symptoms of constipation such as these include colon-stimulating anthraquinone-based crude drug laxatives,
There are small intestinal irritating castor oil, swelling laxatives such as carboxymethylcellulose, salt laxatives such as magnesium sulfate, and sugar laxatives such as sugar alcohols.

【0007】[0007]

【従来の技術と発明が解決しようとする課題】[Prior Art and Problems to be Solved by the Invention]

【0008】しかしながら、従来の下剤には様々な課題
が残されていた。
However, various problems remain in conventional laxatives.

【0009】例えば、前記のアントラキノン系生薬下
剤は骨盤内充血をきたすので、痔疾患患者や妊婦に用い
ることは不適切であり、乳汁移行をするものは授乳期間
中の使用ができないという課題があった。
[0009] For example, the above-mentioned anthraquinone type crude drug laxative causes pelvic hyperemia, so that it is not suitable for use in patients with hemorrhoidal disease and pregnant women, and there is a problem that those that transfer milk cannot be used during lactation. It was

【0010】また、前記のヒマシ油は作用発現までに
要する時間が短いという利点はあるが、服用感が極めて
悪いうえに、一度に20〜30mlもの大量服用が必要
で、更に、他の薬物を服用しているときには脂溶性薬物
の吸収昂進による中毒にも注意する必要があるという課
題があった。
The castor oil described above has the advantage that the time required for the onset of action is short, but it has a very poor feeling of administration and requires a large dose of 20 to 30 ml at a time. There is a problem that it is necessary to pay attention to the poisoning caused by the absorption enhancement of the fat-soluble drug while taking the drug.

【0011】また、前記のカルボキシメチルセルロー
スを初めとする膨張性下剤は、多量の水と共に服用する
ことが必要であり、悪心、嘔吐、腹部膨満感等の不快な
症状とともに、子宮収縮を誘発することがあるので妊婦
への投与はできないという課題があった。
The above-mentioned swelling laxatives such as carboxymethylcellulose must be taken with a large amount of water, and induce uterine contraction along with unpleasant symptoms such as nausea, vomiting and abdominal bloating. Therefore, there was a problem that it cannot be administered to pregnant women.

【0012】また、前記の硫酸マグネシウムを初めと
する塩類下剤は副作用が少ないという利点はあるが、服
用感が悪いうえに効力が弱く、大量の水とともに服用す
る必要があるうえに、塩類下剤自身も多量であることか
ら高齢者等では服用しづらいという課題があった。
Although the above-mentioned salt laxatives such as magnesium sulfate have the advantage that they have few side effects, they are not effective and have a weak effect, and they need to be taken with a large amount of water. Since there is a large amount, it is difficult for the elderly to take.

【0013】更に、前記の糖アルコール類は、非う蝕
性、低カロリーの難消化性甘味剤として広く食品に使用
されており、多量摂取した場合には緩下作用を有するこ
とが知られているので、食品に用いる場合には各々の糖
アルコールの緩下作用の最大無作用量未満になるよう調
整されているが、これらの糖アルコール類の中でもソル
ビトール、ラクチトールが医薬品の下剤として採用され
ている。
Further, the above-mentioned sugar alcohols are widely used in foods as non-cariogenic, low-calorie, indigestible sweeteners, and are known to have a laxative effect when taken in large amounts. Therefore, when used in foods, the laxative effect of each sugar alcohol is adjusted to be less than the maximum no-effect level, but among these sugar alcohols, sorbitol and lactitol are used as laxatives for pharmaceuticals. There is.

【0014】この糖アルコール類は安全性が高く、甘味
を伴うので摂取または服用したときの感じが良好である
という利点はあるが、緩下効果を発現させるには比較的
多量に服用する必要が有り、緩下作用の最大無作用量を
超えた場合には、腹部膨満感、しぶり感、グル音、放
庇、腹痛、嘔気等の不快な症状を呈するという課題があ
った。
These sugar alcohols have the advantage that they are highly safe and have a sweet taste and therefore have a good feeling when ingested or taken, but in order to exert a laxative effect, it is necessary to take a relatively large amount. If the maximum ineffectiveness of laxative action was exceeded, there was a problem that unpleasant symptoms such as abdominal bloating, sensation of swelling, glistening, ejaculation, abdominal pain, and nausea were exhibited.

【0015】一方、各種有機酸は飲料等の酸味剤とし
て、食品ばかりでなく医薬品にも使用されているが、生
体内では吸収されてエネルギーとして利用されると考え
られており、安全性に関する問題は無いが、緩下効果を
有することは知られていない。
On the other hand, various organic acids are used not only as foods but also as medicines as sour agents for beverages and the like, but are considered to be absorbed and used as energy in the living body, which is a safety problem. However, it is not known to have a laxative effect.

【0016】また、前述の硫酸マグネシウム、硫酸ナト
リウム、酸化マグネシウム等の金属塩類は一部が緩下効
果を有することが知られているが、カルシウム塩はカル
シウム補給の目的で摂取され、摂取量によって異なる
が、ラットを用いた試験では約60%が吸収されるとも
言われており、消化管内に多量が残存すれば、難吸収性
の金属塩類と同様の効果を持つ可能性は考えられるが、
その効果は低いものと考えられ、緩下効果を有する組成
物の成分または下剤として使用されてもおらず、且つ、
下剤として認識されてもいなかった。
It is known that some of the above metal salts such as magnesium sulfate, sodium sulfate and magnesium oxide have a laxative effect, but calcium salts are ingested for the purpose of supplementing calcium, and Although it is different, it is also said that about 60% is absorbed in the test using rats, and if a large amount remains in the digestive tract, it may have the same effect as the hardly absorbable metal salts,
The effect is considered to be low, it has not been used as a component of a composition having a laxative effect or as a laxative, and
It was not even recognized as a laxative.

【0017】以上を要するに、便秘は様々な原因によっ
て生じ、原因に応じて大腸刺激性のアントラキノン系生
薬下剤やジフェニルメタン系薬剤、小腸刺激性のヒマシ
油等や塩類、糖類下剤等が使用されているが、これらの
下剤は種々の副作用を有するので、妊婦や、痔、心臓機
能不全、腎臓機能不全等の症状を持っている場合には服
用出来ないか又は適宜下剤の種類や使用方法、併用する
薬剤等を制限する必要があり、安全性の高い下剤の場合
も服用感が不快であったり、腹部膨満感やグル音などの
不快な症状を伴うという課題があったのである。
In summary, constipation is caused by various causes, and depending on the cause, colon-stimulating anthraquinone-based crude drug laxatives, diphenylmethane-based drugs, small intestinal-stimulating castor oil, salts and sugar laxatives are used. However, since these laxatives have various side effects, they cannot be taken if pregnant women or have symptoms such as hemorrhoids, cardiac dysfunction, renal dysfunction, etc. There is a problem that it is necessary to limit the drugs and the like, and even in the case of a highly safe laxative, the feeling of ingestion is uncomfortable, and an unpleasant symptom such as a bloating of the abdomen and a glistening noise is accompanied.

【0018】これらの事情から、安全で且つ摂取または
服用時の感じが良好で、飲食品として摂取できる自然さ
を持ちながら不快な症状を伴わない緩下効果を有する組
成物の開発が要望されていた。
Under these circumstances, there is a demand for the development of a composition which is safe and has a good feeling when ingested or taken, and has a laxative effect which is natural enough to be ingested as a food or drink and does not cause unpleasant symptoms. It was

【0019】[0019]

【課題を解決するための手段】[Means for Solving the Problems]

【0020】本発明者等は、前述の課題を解決するた
め、鋭意検討した結果、有機酸と、単独で服用しても緩
下作用を示さない量の糖アルコールとを併せて摂取した
ときには、糖アルコールを単独で大量に服用した場合に
観察される腹部膨満感等の症状を現さず、有機酸と糖ア
ルコールとが相乗的に作用して緩下効果を呈することを
見出し、更に、有機酸と糖アルコールに加えてカルシウ
ム塩を配合することにより、相乗的な緩下効果が一層増
大することを見出して、優れた緩下作用を有する組成物
を調製することに成功し、本発明を完成するに至った。
In order to solve the above-mentioned problems, the inventors of the present invention have conducted extensive studies and as a result, when ingested together with an organic acid and a sugar alcohol in an amount which does not have a laxative effect when taken alone, It was found that organic acid and sugar alcohol act synergistically to produce a laxative effect without showing symptoms such as abdominal bloating observed when a large amount of sugar alcohol is taken alone. It was found that the synergistic laxative effect was further increased by adding calcium salt in addition to the sugar alcohol and sugar alcohol, and succeeded in preparing a composition having an excellent laxative effect, thus completing the present invention. Came to do.

【0021】即ち、本発明の課題を解決するための手段
は、下記のとおりである。
That is, the means for solving the problems of the present invention are as follows.

【0022】第1に、有機酸と、単独では緩下作用を持
たない量の糖アルコールとを含有することを特徴とす
る、緩下効果を有する組成物。
First, a composition having a laxative effect, which comprises an organic acid and an amount of sugar alcohol which does not have a laxative effect by itself.

【0023】第2に、有機酸と、それぞれ単独では緩下
作用を持たない量の糖アルコール及びカルシウム塩を含
有する、緩下効果を有する組成物。
Secondly, a composition having a laxative effect, which comprises an organic acid and an amount of sugar alcohol and calcium salt which do not have a laxative effect by themselves.

【0024】第3に、糖アルコールが、キシリトール、
ソルビトール、マンニトール、マルチトール、ラクチト
ール、パラチニット、エリスリトール、還元澱粉加水分
解物、イソマルトシルオリゴ糖アルコールから成る群か
ら選ばれる一種または二種以上の混合物である、上記第
1又は第2に記載の緩下効果を有する組成物。
Third, the sugar alcohol is xylitol,
The above-mentioned first or second, which is one kind or a mixture of two or more kinds selected from the group consisting of sorbitol, mannitol, maltitol, lactitol, palatinit, erythritol, reduced starch hydrolyzate and isomaltosyl oligosaccharide alcohol. A composition having a laxative effect.

【0025】第4に、有機酸が、クエン酸、コハク酸、
乳酸、フマル酸、リンゴ酸、酢酸、酒石酸から成る群か
ら選ばれる一種または二種以上の混合物である、上記第
1〜第3の何れか1つに記載の緩下効果を有する組成
物。
Fourth, the organic acids are citric acid, succinic acid,
The composition having a laxative effect according to any one of the first to third aspects, which is one kind or a mixture of two or more kinds selected from the group consisting of lactic acid, fumaric acid, malic acid, acetic acid and tartaric acid.

【0026】第5に、糖アルコール摂取量が、ヒトの体
重1kgあたり、ソルビトールの場合には1〜150mg、
マルチトールの場合には1〜300mg、ラクチトールの
場合には1〜175mg、パラチニットの場合には1〜3
00mg、エリスリトールの場合には1〜760mg、還元
澱粉加水分解物の場合には1〜350mg、イソマルトシ
ルオリゴ糖アルコールの場合には1〜375mgの何れか
の範囲になるように調製した、上記第1〜第4の何れか
1つに記載の緩下効果を有する組成物。
Fifth, sugar alcohol intake is 1 to 150 mg in the case of sorbitol per 1 kg of human body weight,
1-300 mg for maltitol, 1-175 mg for lactitol, 1-3 for palatinit
00 mg, 1 to 760 mg for erythritol, 1 to 350 mg for reduced starch hydrolyzate, and 1 to 375 mg for isomaltosyl oligosaccharide alcohol. The composition having a laxative effect according to any one of the first to fourth aspects.

【0027】第6に、糖アルコール摂取量が、成人一日
あたり、キシリトールの場合には1〜30g、マンニト
ールの場合には1〜20g、二種以上の糖アルコール混
合物を用いる場合には混合物の緩下作用の最大無作用量
未満の何れかの範囲になるように調製した、上記第1〜
第4の何れか1つに記載の緩下効果を有する組成物。
Sixth, sugar alcohol intake is 1 to 30 g in the case of xylitol, 1 to 20 g in the case of mannitol, and a mixture of two or more kinds of sugar alcohol per adult per day. The first to the first, which are prepared so as to fall within any range of the laxative action less than the maximum no-effect amount.
A composition having a laxative effect according to any one of the fourth.

【0028】第7に、糖アルコール摂取量が、ヒトの体
重1kgあたり、ソルビトールの場合には1〜100mg、
マルチトールの場合には1〜200mg、ラクチトールの
場合には1〜117mg、パラチニットの場合には1〜2
00mg、エリスリトールの場合には1〜507mg、還元
澱粉加水分解物の場合には1〜230mg、イソマルトシ
ルオリゴ糖アルコールの場合には1〜250mgの何れか
の範囲になるように調製した、上記第1〜第4の何れか
1つに記載の緩下効果を有する組成物。
Seventh, the sugar alcohol intake is 1 to 100 mg in the case of sorbitol per 1 kg of human body weight,
1-200 mg for maltitol, 1-117 mg for lactitol, 1-2 for palatinit
00 mg, 1-507 mg in the case of erythritol, 1-230 mg in the case of reduced starch hydrolyzate, and 1-250 mg in the case of isomaltosyl oligosaccharide alcohol. The composition having a laxative effect according to any one of the first to fourth aspects.

【0029】第8に、糖アルコール摂取量が、成人一日
あたり、キシリトールの場合には1〜20g、マンニト
ールの場合には1〜14g、二種以上の糖アルコール混
合物を用いる場合には混合物の緩下作用の最大無作用量
の60%未満の何れかの範囲になるように調製した、上
記第1〜第4の何れか1つに記載の緩下効果を有する組
成物。
Eighth, the sugar alcohol intake is 1 to 20 g in the case of xylitol, 1 to 14 g in the case of mannitol, and a mixture of two or more kinds of sugar alcohol per adult per day. The composition having a laxative effect according to any one of the first to fourth aspects, which is prepared so as to fall within a range of less than 60% of a maximum laxative ineffective amount.

【0030】第9に、カルシウム塩摂取量が、ヒトの体
重1kgあたり、カルシウムとして1〜15mgになるよう
に調製した、上記第2〜第8の何れか1つに記載の緩下
効果を有する組成物。
Ninth, it has the laxative effect according to any one of the above second to eighth, which is prepared such that the calcium salt intake is 1 to 15 mg of calcium per 1 kg of human body weight. Composition.

【0031】さらに、本発明の課題を解決するための具
体的な手段の一例を下記に示す。
Further, an example of concrete means for solving the problems of the present invention will be shown below.

【0032】有機酸が、食品であるか又は食品添加物と
して指定されている物質である、上記第1又は第2に記
載の緩下効果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the organic acid is a food or a substance designated as a food additive.

【0033】食品である有機酸としては、米酢、リンゴ
酢、ワインビネガー等の化学的成分としての酢酸等があ
り、これらは食品中に含有されている。
Organic acids as foods include acetic acid as a chemical component of rice vinegar, apple vinegar, wine vinegar and the like, and these are contained in foods.

【0034】食品添加物として指定されている有機酸と
しては、氷酢酸を希釈して調製した酢酸、クエン酸、コ
ハク酸、乳酸、フマル酸、リンゴ酸、酒石酸等がある。
Organic acids designated as food additives include acetic acid prepared by diluting glacial acetic acid, citric acid, succinic acid, lactic acid, fumaric acid, malic acid, tartaric acid and the like.

【0035】有機酸が、乳酸である、上記第1又は第2
に記載の緩下効果を有する組成物。
The above-mentioned first or second organic acid is lactic acid
A composition having a laxative effect according to 1.

【0036】有機酸が、リンゴ酸である、上記第1又は
第2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the organic acid is malic acid.

【0037】有機酸が、クエン酸である、上記第1又は
第2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the first or second aspect, wherein the organic acid is citric acid.

【0038】有機酸が、乳酸とクエン酸との混合物であ
る、上記第1又は第2に記載の緩下効果を有する組成
物。
The composition having a laxative effect according to the first or second aspect, wherein the organic acid is a mixture of lactic acid and citric acid.

【0039】有機酸が、クエン酸とリンゴ酸との混合物
である、上記第1又は第2に記載の緩下効果を有する組
成物。
The composition having a laxative effect according to the above first or second aspect, wherein the organic acid is a mixture of citric acid and malic acid.

【0040】糖アルコールが、食品であるか又は食品添
加物として指定されている物質である、上記第1又は第
2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the sugar alcohol is a food or a substance designated as a food additive.

【0041】食品である糖アルコールとしては、マルチ
トール、ラクチトール、パラチニット、還元澱粉加水分
解物、イソマルトシルオリゴ糖アルコール等がある。
Examples of sugar alcohol which is a food include maltitol, lactitol, palatinit, reduced starch hydrolyzate, isomaltosyl oligosaccharide alcohol and the like.

【0042】食品添加物として指定されている糖アルコ
ールとしては、キシリトール、ソルビトール、マンニト
ール、エリスリトール等がある。
Sugar alcohols designated as food additives include xylitol, sorbitol, mannitol, erythritol and the like.

【0043】糖アルコールが、ソルビトールである、上
記第1又は第2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the sugar alcohol is sorbitol.

【0044】糖アルコールが、還元澱粉加水分解物であ
る、上記第1又は第2に記載の緩下効果を有する組成
物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the sugar alcohol is a reduced starch hydrolyzate.

【0045】糖アルコールが、イソマルトシルオリゴ糖
アルコールである、上記第1又は第2に記載の緩下効果
を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the sugar alcohol is isomaltosyl oligosaccharide alcohol.

【0046】有機酸が、乳酸とクエン酸との混合物であ
り、糖アルコールが、還元澱粉加水分解物である、上記
第1又は第2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the organic acid is a mixture of lactic acid and citric acid, and the sugar alcohol is a reduced starch hydrolyzate.

【0047】カルシウム塩が、食品であるか又は食品添
加物として指定されている物質である、上記第9に記載
の緩下効果を有する組成物。
The composition having a laxative effect according to the above 9th, wherein the calcium salt is a food or a substance designated as a food additive.

【0048】食品であるカルシウム塩としては、各種骨
粉、卵殻などのカルシウム含有食品や牛乳等の食品中に
含有される成分がある。
The calcium salt which is a food includes components contained in calcium-containing foods such as various bone meals and egg shells, and foods such as milk.

【0049】食品添加物として指定されているカルシウ
ム塩としては、クエン酸カルシウム、グルコン酸カルシ
ウム、乳酸カルシウム、ピロリン酸二水素カルシウム、
リン酸三カルシウム、リン酸一水素カルシウム、リン酸
二水素カルシウム等がある。
Calcium salts designated as food additives include calcium citrate, calcium gluconate, calcium lactate, calcium dihydrogen pyrophosphate,
Examples include tricalcium phosphate, calcium monohydrogen phosphate, and calcium dihydrogen phosphate.

【0050】有機酸が、乳酸とクエン酸との混合物であ
り、糖アルコールが、還元澱粉加水分解物であり、カル
シウム塩が塩化カルシウムである、上記第2に記載の緩
下効果を有する組成物。
A composition having a laxative effect according to the above second, wherein the organic acid is a mixture of lactic acid and citric acid, the sugar alcohol is a reduced starch hydrolyzate, and the calcium salt is calcium chloride. .

【0051】単独では緩下作用を持たない量に調節され
た乳酸カルシウム及びマルチトールを含有することを特
徴とする、緩下効果を有する組成物。
A composition having a laxative effect, characterized in that it contains calcium lactate and maltitol adjusted to have no laxative effect alone.

【0052】有機酸がクエン酸であり、糖アルコールが
ソルビトールである、上記第1又は第2に記載の緩下効
果を有する組成物。
The composition having a laxative effect according to the above 1st or 2nd, wherein the organic acid is citric acid and the sugar alcohol is sorbitol.

【0053】有機酸が乳酸であり、糖アルコールがイソ
マルトシルオリゴ糖アルコールである、上記第1又は第
2に記載の緩下効果を有する組成物。
The composition having a laxative effect according to the first or second aspect, wherein the organic acid is lactic acid and the sugar alcohol is isomaltosyl oligosaccharide alcohol.

【0054】本発明に用いる糖アルコールとしては、キ
シリトール、エリスリトール、ソルビトール、マンニト
ール、マルチトール、ラクチトール、パラチニット、還
元澱粉加水分解物、イソマルトシルオリゴ糖アルコール
があり、これらの糖アルコールは甘味や粘度を調節する
等の意味で単独で用いることも、二種以上を組み合わせ
て用いることもできる。
Examples of the sugar alcohol used in the present invention include xylitol, erythritol, sorbitol, mannitol, maltitol, lactitol, palatinit, reduced starch hydrolyzate and isomaltosyl oligosaccharide alcohol, and these sugar alcohols have sweetness and viscosity. Can be used alone or in combination of two or more in the sense of adjusting.

【0055】また、本発明に用いる糖アルコールの品質
は、食品や食品添加物として市販されている程度の品質
で十分で、特別な制約はなく、その形態も、組成物の形
状にあわせて液状、粉末状、顆粒状、スラリー状、固体
状の何れも採用することが出来る。
Further, the quality of the sugar alcohol used in the present invention is sufficient that it is commercially available as a food or a food additive, and there is no particular limitation, and its form is liquid according to the shape of the composition. Any of powder, granule, slurry and solid can be adopted.

【0056】本発明に用いる糖アルコールの配合量は、
糖アルコールを単独で摂取したときに、腹部膨満感やグ
ル音などの不快な症状を伴わない程度の量に調節する必
要があるが、それには、各糖アルコールの緩下効果の最
大無作用量未満に、また、二種以上の糖アルコール混合
物を用いる場合には混合物の緩下作用の最大無作用量未
満になるようにすることが好ましい。
The amount of sugar alcohol used in the present invention is
It is necessary to adjust the amount of sugar alcohol alone without causing unpleasant symptoms such as abdominal bloating and glistening noise, and the maximum no-effect level of the laxative effect of each sugar alcohol. If the mixture of two or more sugar alcohols is used, it is preferable that the laxative action of the mixture is less than the maximum ineffective amount.

【0057】具体的に述べると、各種の糖アルコールの
摂取量は、ヒトの体重1kgあたり、下記のように調製す
ることが好ましい。
Specifically, the intake of various sugar alcohols is preferably adjusted as follows per 1 kg of human body weight.

【0058】ソルビトールの場合には、1〜150mgと
する。マルチトールの場合には、1〜300mgとする。
ラクチトールの場合には、1〜175mgとする。パラチ
ニットの場合には、1〜300mgとする。エリスリトー
ルの場合には、1〜760mgとする。還元澱粉加水分解
物の場合には、1〜350mgとする。イソマルトシルオ
リゴ糖アルコールの場合には、1〜375mgとする。
In the case of sorbitol, the amount is 1 to 150 mg. In the case of maltitol, it is 1 to 300 mg.
In the case of lactitol, the amount is 1-175 mg. In the case of palatinit, it is 1 to 300 mg. In the case of erythritol, the dose is 1 to 760 mg. In the case of reduced starch hydrolyzate, the amount is 1 to 350 mg. In the case of isomaltosyl oligosaccharide alcohol, the amount is 1 to 375 mg.

【0059】また、次の糖アルコールの摂取量は、成人
一日あたり、下記のように調製することが好ましい。
The following sugar alcohol intake is preferably adjusted as follows per adult day.

【0060】キシリトールの場合には、1〜30gとす
る。マンニトールの場合には、1〜20gとする。
In the case of xylitol, the amount is 1 to 30 g. In the case of mannitol, the amount is 1 to 20 g.

【0061】さらに、各種の糖アルコールの摂取量は、
ヒトの体重1kgあたり、下記のように調製することがよ
り好ましい。
Further, the intake of various sugar alcohols is
It is more preferable to prepare as follows per 1 kg of human body weight.

【0062】ソルビトールの場合には、1〜100mgと
する。マルチトールの場合には、1〜200mgとする。
ラクチトールの場合には、1〜117mgとする。パラチ
ニットの場合には、1〜200mgとする。エリスリトー
ルの場合には、1〜507mgとする。還元澱粉加水分解
物の場合には、1〜230mgとする。イソマルトシルオ
リゴ糖アルコールの場合には、1〜250mgとする。
In the case of sorbitol, the amount is 1-100 mg. In the case of maltitol, it is 1 to 200 mg.
In the case of lactitol, the amount is 1-117 mg. In the case of palatinit, it is 1 to 200 mg. In the case of erythritol, the dose is 1 to 507 mg. In the case of reduced starch hydrolyzate, the amount is 1-230 mg. In the case of isomaltosyl oligosaccharide alcohol, the amount is 1-250 mg.

【0063】また、次の糖アルコールの摂取量は、成人
一日あたり、下記のように調製することがより好まし
い。
Further, the following intake of sugar alcohol is more preferably adjusted as follows per adult day.

【0064】キシリトールの場合には、1〜20gとす
る。マンニトールの場合には、1〜14gとする。
In the case of xylitol, the amount is 1 to 20 g. In the case of mannitol, the amount is 1 to 14 g.

【0065】二種以上の糖アルコール混合物を用いる場
合には、混合物の緩下作用の最大無作用量の60%未満
の何れかの範囲になるように、摂取する組成物中の存在
量を調節するか又は組成物の摂取量を調節することが最
も好ましい。
When a mixture of two or more sugar alcohols is used, the amount present in the ingested composition is adjusted so as to fall within any range of less than 60% of the maximum ineffectiveness of the laxative effect of the mixture. Most preferably, or controlling the intake of the composition.

【0066】糖アルコールの使用量が上記各範囲の下限
未満の場合には、本発明の効果である緩下作用が発現し
ない場合があり、また、各範囲の上限を超えた場合に
は、例えその量が各糖アルコールの最大無作用量未満で
あっても、腹部膨満感、しぶり感、グル音、放庇、腹
痛、嘔気等の不快な症状を呈することがあるので好まし
くない。
If the amount of sugar alcohol used is less than the lower limit of each of the above ranges, the laxative effect, which is the effect of the present invention, may not be exhibited, and if it exceeds the upper limit of each range, for example, Even if the amount is less than the maximum no-effect amount of each sugar alcohol, unpleasant symptoms such as abdominal bloating, tingling sensation, glistening, erecting, abdominal pain, and nausea may be exhibited, which is not preferable.

【0067】本発明に用いる有機酸としては、クエン
酸、コハク酸、乳酸、フマル酸、リンゴ酸、酢酸、酒石
酸があり、これらの有機酸は酸味や甘味を調節する等の
意味で単独で用いることも、二種以上を組み合わせて用
いることもできる。
The organic acids used in the present invention include citric acid, succinic acid, lactic acid, fumaric acid, malic acid, acetic acid and tartaric acid, and these organic acids are used alone for the purpose of controlling sourness and sweetness. It is also possible to use two or more types in combination.

【0068】本発明の組成物の効果を顕著に表わすため
には、上記の有機酸の中でも乳酸が最も好ましい。
Among the above-mentioned organic acids, lactic acid is most preferable in order to remarkably exhibit the effects of the composition of the present invention.

【0069】また、本発明に用いる有機酸の形態につい
ても格別の制約は無く、本発明の組成物の形状にあわせ
て各種形態の酸を採用すればよい。
There are no particular restrictions on the form of the organic acid used in the present invention, and various forms of acid may be adopted according to the shape of the composition of the present invention.

【0070】本発明に用いる有機酸の量は、使用する糖
アルコール量の1/50〜2倍程度が最も好ましいが、
糖アルコールと有機酸とを併用するうえで、あまり極端
な配合をして服用感を著しく損なわないかぎり、前記の
範囲を少々外れても本発明の優れた効果を期待すること
ができる。
The amount of organic acid used in the present invention is most preferably about 1/50 to 2 times the amount of sugar alcohol used,
When the sugar alcohol and the organic acid are used in combination, the excellent effect of the present invention can be expected even if the above range is slightly exceeded unless the composition is excessively blended to significantly impair the feeling of ingestion.

【0071】本発明に用いるカルシウム塩としては、塩
化カルシウム、炭酸カルシウム、硫酸カルシウム、ピロ
リン酸カルシウム等の各種リン酸カルシウムなどの無機
カルシウム塩類の他にも、各種有機酸のカルシウム塩を
用いることができる。
As the calcium salt used in the present invention, in addition to inorganic calcium salts such as various calcium phosphates such as calcium chloride, calcium carbonate, calcium sulfate and calcium pyrophosphate, calcium salts of various organic acids can be used.

【0072】各種有機酸のカルシウム塩を用いた場合に
は、有機酸とカルシウムとを同時に、クエン酸カルシウ
ム、グルコン酸カルシウム、乳酸カルシウム、リンゴ酸
カルシウムなどとして配合することもできる。
When calcium salts of various organic acids are used, the organic acid and calcium can be simultaneously mixed as calcium citrate, calcium gluconate, calcium lactate, calcium malate and the like.

【0073】また、本発明に用いるカルシウム塩の品質
は、本発明の目的物である緩下効果をもった食品または
医薬品として採用可能な範囲、つまり、医薬品材料、食
品又は食品添加物として採用可能なものであれば、特別
な制約は無く、本発明に用いるカルシウム塩の形態も本
発明の組成物の形態に応じて自由に適切な形態のものを
採用することができる。
The quality of the calcium salt used in the present invention can be adopted as a food or drug having a laxative effect, which is the object of the present invention, that is, as a pharmaceutical material, food or food additive. There is no particular limitation so long as the calcium salt used in the present invention has any suitable form depending on the form of the composition of the present invention.

【0074】本発明に用いるカルシウム塩の量は、カル
シウムとしてヒトの体重1kgあたり、1〜15mgとす
ることが好ましいが、糖アルコールの量に対しては、1
/50〜1/2倍の範囲にすることが更に好ましく、有
機酸の量に対しては、1/25〜1倍の範囲にすること
が更に好ましい。
The amount of calcium salt used in the present invention is preferably 1 to 15 mg per 1 kg of human body weight as calcium.
It is more preferably in the range of / 50 to 1/2, and more preferably in the range of 1/25 to 1 with respect to the amount of the organic acid.

【0075】カルシウム塩の使用量が前記の好ましい範
囲を外れた場合には、カルシウム塩による本発明の相乗
的効果がやや低下したり、服用感が悪くなったりするこ
とが多いので、本発明の好ましい実施態様を外れた量の
カルシウム塩を用いる意味が無い。
If the amount of the calcium salt used is outside the above preferred range, the synergistic effect of the present invention due to the calcium salt may be slightly reduced or the feeling of ingestion may be deteriorated. There is no point in using an amount of calcium salt outside the preferred embodiment.

【0076】本発明者等の知見によれば、糖アルコール
と有機酸を併用する本発明の組成物は、更にカルシウム
塩を用いることによって緩下効果が一層高まり、服用感
も良好になるが、効果的な使用割合は、カルシウム塩の
カルシウム使用量を1重量部としたときに、有機酸1〜
25重量部、糖アルコール2〜50重量部であり、最も
効果的な使用割合は、カルシウム塩のカルシウム使用量
を1重量部としたときに、有機酸5〜20重量部、糖ア
ルコール10〜30重量部である。
According to the knowledge of the present inventors, the composition of the present invention in which a sugar alcohol and an organic acid are used in combination has a laxative effect further enhanced by further using a calcium salt. The effective usage ratio is 1% by weight of the organic acid when the amount of calcium used in the calcium salt is 1 part by weight.
25 parts by weight and sugar alcohol 2 to 50 parts by weight. The most effective use ratio is 5 to 20 parts by weight of organic acid and 10 to 30 parts of sugar alcohol when the amount of calcium used in the calcium salt is 1 part by weight. Parts by weight.

【0077】本発明の組成物は、保健や美容を目的とす
る食品、飲料や、嗜好品、飼料、医薬品として、シロッ
プやドリンク剤のような液状、スラリー状、粉末状、顆
粒状、固体状等の公知の各種形状にすることができる
が、本発明の組成物に使用する以外の各種材料と任意の
割合で混合、併用することが可能で、例えば混和、混
捏、溶解、浸漬、浸透、散布、塗布、被覆、噴霧、注
入、晶出、固化などの公知の方法によって製品が完成す
るまでの何れかの工程で本発明の組成物を含有させるこ
とができる。
The composition of the present invention is used as a food, a beverage, a favorite product, a feed, or a medicine for health and beauty purposes, such as a syrup or a drink, a liquid, a slurry, a powder, a granule or a solid. Although it can be formed into various known shapes such as, it can be mixed with various materials other than those used in the composition of the present invention at any ratio, and can be used in combination, for example, kneading, kneading, dissolving, dipping, penetrating, The composition of the present invention can be contained in any step until the product is completed by known methods such as spraying, coating, coating, spraying, pouring, crystallization, and solidification.

【0078】以上に説明した本発明の組成物は、単独で
は緩下効果の無い有機酸によって糖アルコール緩下効果
を増大させつつ、糖アルコールを単独で服用した後に残
る不快な症状を解消し、単独では逆に便秘を昂進するこ
とがあるカルシウム塩によって更に緩下効果を高め、良
好な服用感を呈するという優れた性質を有するものであ
る。
The composition of the present invention described above eliminates the unpleasant symptoms that remain after taking sugar alcohol alone while increasing the sugar alcohol laxative effect by an organic acid that has no laxative effect alone. On the contrary, it has an excellent property that the laxative effect is further enhanced by the calcium salt which may promote constipation by itself, and a good feeling of ingestion is exhibited.

【0079】以下に、試験例、実施例を掲げて更に具体
的に本発明について説明するが、本発明の技術的範囲は
以下の例に制限されるものではない。
Hereinafter, the present invention will be described more specifically with reference to Test Examples and Examples, but the technical scope of the present invention is not limited to the following examples.

【0080】また、以下の例において、%は特に断らな
い限り重量%を表わすものとする。
In the following examples,% means% by weight unless otherwise specified.

【0081】[0081]

【試験例】[Test example]

【0082】5週齢の体重20〜25gのオスのddY
系マウス[日本エスエルシー(株)製]を個体として用
い、表1の検体処方一覧に示すように異なる成分の検体
1〜検体5の試験用として、1検体あたり各20匹のマ
ウスに、実験まで飼料と水とを自由に与えた。
Male ddY, 5 weeks old, weighing 20-25 g
Strain mouse [manufactured by Japan SLC Co., Ltd.] was used as an individual, and as shown in the sample prescription list in Table 1, for the tests of Sample 1 to Sample 5 having different components, an experiment was conducted using 20 mice per sample. Was allowed food and water ad libitum.

【0083】[0083]

【表1】 [Table 1]

【0084】そして、各々のマウスに、ゾンデを用いて
各検体0.4mlを経胃投与後、絶食、絶水とし、ろ紙
上に糞便を排出させた。
Then, 0.4 ml of each sample was intragastrically administered to each mouse using a sonde, followed by fasting and water-free, and feces were discharged on a filter paper.

【0085】これをガラス容器に集めて、丹羽らの方法
[丹羽弘司、引地登、桜井栄一、佐々木和彦、植田公
孝、硫酸マグネシウム誘発下痢時のセロトニン、ヒスタ
ミン、ポリアミン量と薬物の消化管吸収、薬剤学、4
0、32−41(1980)]を参考として、表2の糞
便の外観評価基準により、各検体の緩下作用を20匹を
1群として評価し、緩下作用の評価結果を緩下効果の発
生率(%)に換算して表3に示した。
Collect this in a glass container and use the method of Niwa et al. Pharmacy, 4
0, 32-41 (1980)], the laxative effect of each sample was evaluated as a group of 20 animals according to the appearance evaluation criteria of feces in Table 2, and the laxative effect was evaluated as a laxative effect. The occurrence rate (%) is shown in Table 3.

【0086】[0086]

【表2】 [Table 2]

【0087】[0087]

【表3】 [Table 3]

【0088】表3に示す結果のように、単独では緩下作
用を示さない量の糖アルコールに有機酸を加えることに
より緩下作用を生じ、この作用はカルシウム塩を添加す
ることで更に効果的であった。
As shown in the results shown in Table 3, the laxative effect is produced by adding an organic acid to an amount of sugar alcohol which does not have a laxative effect by itself, and this effect is more effective by adding a calcium salt. Met.

【0089】[0089]

【実施例1】[Example 1]

【0090】還元澱粉加水分解物[東和化成工業(株)
製、製品名PO−40]8000mg、乳酸(50%)
2000mg、クエン酸2000mgを精製水に溶解
し、これに安息香酸Na50mgを溶解してから、更
に、適量の水酸化Naを加えてpH4.0に調整した。
Reduced starch hydrolyzate [Towa Kasei Co., Ltd.
Made, product name PO-40] 8000 mg, lactic acid (50%)
2000 mg and citric acid 2000 mg were dissolved in purified water, and Na benzoate 50 mg was dissolved therein, and then an appropriate amount of Na hydroxide was added to adjust the pH to 4.0.

【0091】なお、上記で用いた還元澱粉加水分解物
[東和化成工業(株)製、製品名PO−40]の標準糖組
成は、下記のとおりである。
The standard sugar composition of the reduced starch hydrolyzate [Product name: PO-40, manufactured by Towa Kasei Kogyo Co., Ltd.] used above is as follows.

【0092】1糖(ソルビット)が1〜5%、2糖(マ
ルチトール)が50〜55%、3糖(マルトトリイトー
ル)が17〜25%、4糖以上(オリゴ糖アルコール)
が23〜30%である。
1 to 5% of saccharide (sorbit), 50 to 55% of 2 saccharide (maltitol), 17 to 25% of 3 saccharide (maltotriitol), 4 or more saccharide (oligosaccharide alcohol)
Is 23 to 30%.

【0093】この水溶液を精製水で全量100mlと
し、ろ紙でろ過した後、全量をガラス瓶に充填してアル
ミキャップを締め、加熱殺菌して本発明の組成物1(内
用液剤)を得た。
The total amount of this aqueous solution was adjusted to 100 ml with purified water, filtered through a filter paper, the total amount was filled in a glass bottle, an aluminum cap was closed, and heat sterilization was performed to obtain a composition 1 (internal liquid preparation) of the present invention.

【0094】[0094]

【実施例2】Example 2

【0095】還元澱粉加水分解物[東和化成工業(株)
製、製品名PO−60]8000mg、乳酸(50%)
2000mg、クエン酸2000mg、塩化カルシウム
2000mgを精製水に溶解し、これに安息香酸Na5
0mgを溶解してから、更に、適量の水酸化Naを加え
てpH4.0に調整した。
Reduced starch hydrolyzate [Towa Chemical Industry Co., Ltd.
Made, product name PO-60] 8000 mg, lactic acid (50%)
2000 mg, citric acid 2000 mg, calcium chloride 2000 mg were dissolved in purified water, and Na5 benzoate was added to the solution.
After dissolving 0 mg, an appropriate amount of sodium hydroxide was further added to adjust the pH to 4.0.

【0096】なお、上記で用いた還元澱粉加水分解物
[東和化成工業(株)製、製品名PO−60]の標準糖組
成は、下記のとおりである。
The standard sugar composition of the reduced starch hydrolyzate [product name: PO-60, manufactured by Towa Kasei Co., Ltd.] used above is as follows.

【0097】1糖(ソルビット)が2〜4%、2糖(マ
ルチトール)が63〜67%、3糖(マルトトリイトー
ル)が13〜18%、4糖以上(オリゴ糖アルコール)
が13〜18%である。
1 to 4 sugars (sorbit) 2 to 4%, 2 sugars (maltitol) 63 to 67%, 3 sugars (maltotriitol) 13 to 18%, 4 sugars or more (oligosaccharide alcohol)
Is 13 to 18%.

【0098】この水溶液を精製水で全量100mlと
し、その後は実施例1と同様にして本発明の組成物2
(内用液剤)を得た。
This aqueous solution was made up to 100 ml with purified water, and then the composition 2 of the present invention was processed in the same manner as in Example 1.
(Liquid for internal use) was obtained.

【0099】[0099]

【実施例3】Example 3

【0100】カカオベース37重量部、カカオバター1
1重量部、乳酸カルシウム15重量部、マルチトール
[東和化成工業(株)製、製品名アマルティMR]36.
4重量部を混合してリファイナーに通して粒度をそろえ
た後、コンチエに入れ、レシチン0.6重量部を加えて
47℃にて2昼夜混練した後、温度を30℃とし、振盪
機で気泡を十分に除去した後、型に流し、8℃にて15
分間冷却して型から外し、20gを1つの包装として本
発明の組成物3(チョコレート)を得た。
37 parts by weight of cocoa base, 1 cocoa butter
1 part by weight, calcium lactate 15 parts by weight, maltitol [manufactured by Towa Kasei Kogyo KK, product name Amarti MR] 36.
After mixing 4 parts by weight and passing through a refiner to adjust the particle size, put in a contier, add 0.6 parts by weight of lecithin and knead at 47 ° C for 2 days and nights, then bring the temperature to 30 ° C, and bubble with a shaker. After removing enough, pour into a mold,
After cooling for 1 minute and removing from the mold, the composition 3 (chocolate) of the present invention was obtained by packaging 20 g as one package.

【0101】[0101]

【実施例4】Example 4

【0102】レモン油0.21重量部、飲料用アルコー
ル8.93重量部、クエン酸10.00重量部、サッカ
リンナトリウム0.21重量部、水10.65重量部、
35%ソルビトール水溶液[東和化成工業(株)製、製品
名ソルビットD−70]70.00重量部からなる水溶
液1重量部に炭酸水6重量部を加え、250mlのビン
に詰めて密栓をし、本発明の組成物4(清涼飲料)を得
た。
0.21 parts by weight of lemon oil, 8.93 parts by weight of alcohol for beverages, 10.00 parts by weight of citric acid, 0.21 parts by weight of sodium saccharin, 10.65 parts by weight of water,
6 parts by weight of carbonated water was added to 1 part by weight of an aqueous solution consisting of 70.00 parts by weight of a 35% sorbitol aqueous solution [Product name: Solbit D-70, manufactured by Towa Kasei Kogyo Co., Ltd.], and the mixture was filled in a 250 ml bottle and sealed. A composition 4 (soft drink) of the present invention was obtained.

【0103】[0103]

【実施例5】Example 5

【0104】ホエー蛋白6重量部、乳脂10重量部、ゼ
ラチン0.25重量部、乳化剤[(株)花王製、アトモス
150]0.25重量部、イソマルトシルオリゴ糖アル
コール[東和化成工業(株)製、PO−500]21.5
重量部、水62重量部を60℃まで加温しながら各成分
を混合溶解し、ホモジナイザーで強く撹拌して乳化した
後、90℃にて3分間加熱殺菌してバニラエッセンス少
量を添加し、一つ100gのカップに分け、クエン酸カ
ルシウム3g及びリンゴ酸ナトリウム1gと市販のスト
ロベリージャム20gとの混合物をクリームの上に乗
せ、零下5℃で徐冷した後、零下30℃で急速に冷凍し
て硬化させ、零下20℃にて保存して本発明の組成物5
(フローズンデザート)を得た。
6 parts by weight of whey protein, 10 parts by weight of milk fat, 0.25 part by weight of gelatin, 0.25 part by weight of emulsifier [Atomos 150, manufactured by Kao Corporation], isomaltosyl oligosaccharide alcohol [Towa Chemical Industry Co., Ltd. ), PO-500] 21.5
While heating 62 parts by weight of water and 60 parts by weight of water to 60 ° C., the components are mixed and dissolved, and the mixture is strongly stirred with a homogenizer to emulsify and then heat sterilized at 90 ° C. for 3 minutes to add a small amount of vanilla essence. Divide into 100 g cups, put a mixture of 3 g of calcium citrate and 1 g of sodium malate and 20 g of commercially available strawberry jam on the cream, slowly cool at 5 ° C below zero, and then quickly freeze at 30 ° C below zero. Cured and stored at 20 ° C. below zero, composition 5 of the present invention
I got (frozen dessert).

【0105】[0105]

【比較例1】[Comparative Example 1]

【0106】還元澱粉加水分解物[東和化成工業(株)
製、製品名PO−40]8000mgを精製水に溶解
し、これにパラオキシ安息香酸エチル10mgを溶解し
てから、更に、この水溶液を精製水で全量100mlと
し、その後は実施例1と同様にして比較品1を得た。
Reduced starch hydrolyzate [Towa Kasei Co., Ltd.
Manufactured, product name PO-40] 8000 mg was dissolved in purified water, ethyl paraoxybenzoate 10 mg was dissolved in this, and the total amount of this aqueous solution was further adjusted to 100 ml with purified water, and thereafter, in the same manner as in Example 1. Comparative product 1 was obtained.

【0107】[0107]

【比較例2】[Comparative Example 2]

【0108】塩化カルシウム2000mgを精製水に溶
解し、これに白糖10g、パラオキシ安息香酸エチル1
0mgを溶解してから、更に、この水溶液を精製水で全
量100mlとし、その後は実施例1と同様にして比較
品2を得た。
2000 mg of calcium chloride was dissolved in purified water, to which 10 g of sucrose and 1 part of paraoxybenzoate were added.
After dissolving 0 mg, the total amount of the aqueous solution was further adjusted to 100 ml with purified water, and then Comparative Example 2 was obtained in the same manner as in Example 1.

【0109】[0109]

【比較例3】[Comparative Example 3]

【0110】乳酸(50%)2000mg及びクエン酸
2000mgを精製水に溶解し、これに白糖10g、安
息香酸Na50mgを溶解してから、更に、適量の水酸
化Naを加えてpH4.0に調整して、この水溶液を精
製水で全量100mlとし、その後は実施例1と同様に
して比較品3を得た。
2000 mg of lactic acid (50%) and 2000 mg of citric acid were dissolved in purified water, 10 g of sucrose and 50 mg of Na benzoate were dissolved therein, and then an appropriate amount of sodium hydroxide was added to adjust the pH to 4.0. Then, the total amount of this aqueous solution was made up to 100 ml with purified water, and then Comparative Example 3 was obtained in the same manner as in Example 1.

【0111】[0111]

【比較例4】[Comparative Example 4]

【0112】還元澱粉加水分解物[東和化成工業(株)
製、製品名PO−60]8000mg及び塩化カルシウ
ム2000mgを精製水に溶解し、これにパラオキシ安
息香酸エチル10mgを溶解して、この水溶液を精製水
で全量100mlとし、その後は実施例1と同様にして
比較品4を得た。
Reduced starch hydrolyzate [Towa Kasei Co., Ltd.
Manufactured, product name PO-60] 8000 mg and calcium chloride 2000 mg were dissolved in purified water, ethyl paraoxybenzoate 10 mg was dissolved in this, and the total amount of this aqueous solution was 100 ml with purified water, and thereafter the same as in Example 1. Comparative product 4 was obtained.

【0113】[0113]

【比較例5】[Comparative Example 5]

【0114】乳酸(50%)2000mg、クエン酸2
000mg、塩化カルシウム2000mgを精製水に溶
解し、これに白糖10g、安息香酸Na50mgを溶解
してから、更に、適量の水酸化Naを加えてpH4.0
に調整して、この水溶液を精製水で全量100mlと
し、その後は実施例1と同様にして比較品5を得た。
Lactic acid (50%) 2000 mg, citric acid 2
000 mg and 2000 mg of calcium chloride were dissolved in purified water, 10 g of sucrose and 50 mg of Na benzoate were dissolved therein, and then an appropriate amount of sodium hydroxide was added to pH 4.0.
The total amount of this aqueous solution was adjusted to 100 ml with purified water, and then Comparative Example 5 was obtained in the same manner as in Example 1.

【0115】[0115]

【比較試験】[Comparison test]

【0116】実施例1〜実施例5で得た本発明の組成物
1〜組成物5と、比較例1〜比較例5で得た比較品1〜
比較品5とを、体重56±8.4kgの健康な成人男女
20名に経口投与し、24時間後までに、緩下作用を示
した人数、及び、腹部膨満感、しぶり感、放屁、グル
音、腹痛、嘔気等の不快症状を呈した人数を調べること
で、緩下作用の効果と副作用を比較する試験を行なっ
た。
Compositions 1 to 5 of the present invention obtained in Examples 1 to 5 and comparative products 1 to 1 obtained in Comparative Examples 1 to 5
Comparative product 5 was orally administered to 20 healthy adult men and women with a body weight of 56 ± 8.4 kg, and by 24 hours, the number of laxative effects, abdominal bloating, sensation of feeling, flatus, A test was conducted to compare the effects of laxative effects and side effects by examining the number of people who exhibited unpleasant symptoms such as whirring, abdominal pain, and nausea.

【0117】なお、試験の順序はランダマイズし、被験
製剤には乱数を付し、ブラインドテストとした。
The order of the tests was randomized, the test preparations were given random numbers, and blind tests were conducted.

【0118】試験の結果を表4に示す。The results of the tests are shown in Table 4.

【0119】[0119]

【表4】 [Table 4]

【0120】表4から明らかなように、比較例では全く
緩下作用が認められなかったのに対して、実施例では何
れも高い割合で緩下作用を示し、更に、実施例には腹部
膨満感、放屁、グル音などの不快な症状が認められなか
った。
As is clear from Table 4, no laxative effect was observed in the comparative examples, whereas the laxative effects were high in all of the Examples. There were no unpleasant symptoms such as feeling, flatus, and guru.

【0121】[0121]

【発明の効果】【The invention's effect】

【0122】本発明の緩下効果を有する組成物は、安全
で且つ摂取または服用時の感じが良好で、飲食品として
摂取できる自然さを持ちながら不快な症状を伴わない緩
下効果を有する組成物であり、糖アルコールや他の成分
をそれぞれ単独で用いた場合よりも少ない量で相乗的な
緩下効果を持ち、且つ、安全性が高く、しかも、腹部膨
満感、放屁、グル音等の糖アルコールを用いた場合に見
られる不快な症状がほとんど無いことから、排便促進効
果や緩下効果を有する組成物として極めて有効で、糖尿
病患者にも悪影響が出にくいという特徴も備えており、
従来品よりも幅広い対象者に使用することができる。
The composition having a laxative effect of the present invention is a composition which is safe and has a good feeling when ingested or taken, and has a natural laticity that can be ingested as a food or drink, but has no laxative effect. It has a synergistic laxative effect with a smaller amount than the case of using sugar alcohol and other components alone, and is highly safe, and moreover, the abdominal bloating, flatus, glistening noise, etc. Since there is almost no unpleasant symptom seen when using sugar alcohol, it is extremely effective as a composition having a defecation promoting effect and laxative effect, and also has a characteristic that a diabetic patient is unlikely to be adversely affected.
It can be used for a wider range of subjects than conventional products.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 (A61K 31/19 31:045 33:06) (72)発明者 櫻井 英知 埼玉県大里郡江南町大字押切字沼上2512− 1 ゼリア新薬工業株式会社中央研究所内 (72)発明者 金子 由公 東京都中央区八重洲2−8−7 東和化成 工業株式会社内 (72)発明者 加藤 和昭 東京都中央区八重洲2−8−7 東和化成 工業株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI technical indication location (A61K 31/19 31: 045 33:06) (72) Inventor Hidetomo Sakurai Konan Town, Osato County, Saitama Prefecture 2512-1 Numagami Oshikiriji Central Research Institute, Zeria Shinyaku Kogyo Co., Ltd. (72) Inventor, Yuko Kaneko 2-8-7 Yaesu, Chuo-ku, Tokyo Towa Kasei Kogyo Co., Ltd. (72) Inventor, Kazuaki Kato Central Tokyo 2-8-7 Yaesu-ku, Towa Kasei Kogyo Co., Ltd.

Claims (9)

【特許請求の範囲】[Claims] 【請求項1】 有機酸と、単独では緩下作用を持たない
量の糖アルコールとを含有することを特徴とする、緩下
効果を有する組成物。
1. A composition having a laxative effect, which comprises an organic acid and an amount of sugar alcohol which does not have a laxative effect by itself.
【請求項2】 有機酸と、それぞれ単独では緩下作用を
持たない量の糖アルコール及びカルシウム塩を含有す
る、緩下効果を有する組成物。
2. A composition having a laxative effect, which comprises an organic acid and an amount of sugar alcohol and calcium salt which do not have a laxative effect by themselves.
【請求項3】 糖アルコールが、キシリトール、ソルビ
トール、マンニトール、マルチトール、ラクチトール、
パラチニット、エリスリトール、還元澱粉加水分解物、
イソマルトシルオリゴ糖アルコールから成る群から選ば
れる一種または二種以上の混合物である、請求項1又は
2に記載の緩下効果を有する組成物。
3. The sugar alcohol is xylitol, sorbitol, mannitol, maltitol, lactitol,
Palatinit, erythritol, reduced starch hydrolyzate,
The composition having a laxative effect according to claim 1 or 2, which is one kind or a mixture of two or more kinds selected from the group consisting of isomaltosyl oligosaccharide alcohols.
【請求項4】 有機酸が、クエン酸、コハク酸、乳酸、
フマル酸、リンゴ酸、酢酸、酒石酸から成る群から選ば
れる一種または二種以上の混合物である、請求項1〜3
の何れか1つに記載の緩下効果を有する組成物。
4. The organic acid is citric acid, succinic acid, lactic acid,
4. One or a mixture of two or more selected from the group consisting of fumaric acid, malic acid, acetic acid and tartaric acid.
A composition having a laxative effect according to any one of 1.
【請求項5】 糖アルコール摂取量が、ヒトの体重1kg
あたり、ソルビトールの場合には1〜150mg、マルチ
トールの場合には1〜300mg、ラクチトールの場合に
は1〜175mg、パラチニットの場合には1〜300m
g、エリスリトールの場合には1〜760mg、還元澱粉
加水分解物の場合には1〜350mg、イソマルトシルオ
リゴ糖アルコールの場合には1〜375mgの何れかの範
囲になるように調製した、請求項1〜4の何れか1つに
記載の緩下効果を有する組成物。
5. The intake of sugar alcohol is 1 kg of human body weight.
In the case of sorbitol, 1 to 150 mg, in the case of maltitol, 1 to 300 mg, in the case of lactitol, 1 to 175 mg, in the case of palatinit, 1 to 300 m.
g, 1 to 760 mg in the case of erythritol, 1 to 350 mg in the case of reduced starch hydrolyzate, and 1 to 375 mg in the case of isomaltosyl oligosaccharide alcohol. Item 5. A composition having a laxative effect according to any one of Items 1 to 4.
【請求項6】 糖アルコール摂取量が、成人一日あた
り、キシリトールの場合には1〜30g、マンニトール
の場合には1〜20g、二種以上の糖アルコール混合物
を用いる場合には混合物の緩下作用の最大無作用量未満
の何れかの範囲になるように調製した、請求項1〜4の
何れか1つに記載の緩下効果を有する組成物。
6. The intake of sugar alcohol per adult per day is 1 to 30 g in the case of xylitol, 1 to 20 g in the case of mannitol, and laxative of the mixture when a mixture of two or more sugar alcohols is used. The composition having a laxative effect according to any one of claims 1 to 4, which is prepared so as to have a range of less than the maximum no-effect level of action.
【請求項7】 糖アルコール摂取量が、ヒトの体重1kg
あたり、ソルビトールの場合には1〜100mg、マルチ
トールの場合には1〜200mg、ラクチトールの場合に
は1〜117mg、パラチニットの場合には1〜200m
g、エリスリトールの場合には1〜507mg、還元澱粉
加水分解物の場合には1〜230mg、イソマルトシルオ
リゴ糖アルコールの場合には1〜250mgの何れかの範
囲になるように調製した、請求項1〜4の何れか1つに
記載の緩下効果を有する組成物。
7. The intake of sugar alcohol is 1 kg of human body weight.
So, 1-100 mg for sorbitol, 1-200 mg for maltitol, 1-117 mg for lactitol, 1-200 m for palatinit.
g, 1 to 507 mg in the case of erythritol, 1 to 230 mg in the case of a reduced starch hydrolyzate, and 1 to 250 mg in the case of isomaltosyl oligosaccharide alcohol. Item 5. A composition having a laxative effect according to any one of Items 1 to 4.
【請求項8】 糖アルコール摂取量が、成人一日あた
り、キシリトールの場合には1〜20g、マンニトール
の場合には1〜14g、二種以上の糖アルコール混合物
を用いる場合には混合物の緩下作用の最大無作用量の6
0%未満の何れかの範囲になるように調製した、請求項
1〜4の何れか1つに記載の緩下効果を有する組成物。
8. The intake of sugar alcohol per adult per day is 1 to 20 g in the case of xylitol, 1 to 14 g in the case of mannitol, and laxative of the mixture when a mixture of two or more sugar alcohols is used. Maximum no effect of action 6
The composition having a laxative effect according to any one of claims 1 to 4, which is prepared so as to fall within a range of less than 0%.
【請求項9】 カルシウム塩摂取量が、ヒトの体重1kg
あたり、カルシウムとして1〜15mgになるように調製
した、請求項2〜8の何れか1つに記載の緩下効果を有
する組成物。
9. The calcium salt intake is 1 kg of human body weight.
The composition having a laxative effect according to any one of claims 2 to 8, which is prepared to have a calcium content of 1 to 15 mg.
JP5440994A 1994-03-01 1994-03-01 Composition having a laxative effect Expired - Fee Related JP3850891B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5440994A JP3850891B2 (en) 1994-03-01 1994-03-01 Composition having a laxative effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5440994A JP3850891B2 (en) 1994-03-01 1994-03-01 Composition having a laxative effect

Publications (2)

Publication Number Publication Date
JPH07242539A true JPH07242539A (en) 1995-09-19
JP3850891B2 JP3850891B2 (en) 2006-11-29

Family

ID=12969910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5440994A Expired - Fee Related JP3850891B2 (en) 1994-03-01 1994-03-01 Composition having a laxative effect

Country Status (1)

Country Link
JP (1) JP3850891B2 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116945A1 (en) * 1997-01-14 1998-07-16 Soler Ribatallada Ernest Laxative composition and process for preparing it
EP0988797A4 (en) * 1996-10-08 2001-10-04 Meiji Seika Co Compositions for postgastrectomic mineral supply
JP2004242523A (en) * 2003-02-12 2004-09-02 Q P Corp Test food for colonoscopy
JP2008266203A (en) * 2007-04-19 2008-11-06 Bussan Food Science Kk Method for improving activity of reactive oxygen species-scavenging enzyme group
US20110223252A1 (en) * 2002-03-04 2011-09-15 Thomas Julius Borody Electrolyte purgative
US9308226B2 (en) 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (en) 2011-03-11 2016-06-01 諾金私人有限公司 Colon cleansing solution, composition for preparing the solution, kit comprising the composition or solution, and method of preparing the same
KR20170098980A (en) 2012-09-11 2017-08-30 노어긴 비.브이. Compositions comprising peg and ascorbate

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988797A4 (en) * 1996-10-08 2001-10-04 Meiji Seika Co Compositions for postgastrectomic mineral supply
ES2116945A1 (en) * 1997-01-14 1998-07-16 Soler Ribatallada Ernest Laxative composition and process for preparing it
US9623056B2 (en) 2000-07-20 2017-04-18 Crestovo Llc Probiotic recolonisation therapy
US10369175B2 (en) 2000-07-25 2019-08-06 Crestovo Holdings Llc Probiotic recolonisation therapy
US9962414B2 (en) 2000-07-25 2018-05-08 Crestovo Holdings Llc Probiotic recolonisation therapy
US10772919B2 (en) 2000-07-25 2020-09-15 Crestovo Holdings Llc Probiotic recolonisation therapy
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9610308B2 (en) 2000-07-25 2017-04-04 Crestovo Llc Probiotic recolonisation therapy
US9682108B2 (en) 2000-07-25 2017-06-20 Crestovo Llc Probiotic recolonisation therapy
US9789140B2 (en) 2000-07-25 2017-10-17 Crestovo Holdings Llc Probiotic recolonisation therapy
US9867858B2 (en) 2000-07-25 2018-01-16 Crestovo Holdings Llc Probiotic recolonisation therapy
US9901604B2 (en) 2000-07-25 2018-02-27 Crestovo Holdings Llc Probiotic recolonisation therapy
US20110223252A1 (en) * 2002-03-04 2011-09-15 Thomas Julius Borody Electrolyte purgative
JP2004242523A (en) * 2003-02-12 2004-09-02 Q P Corp Test food for colonoscopy
JP2008266203A (en) * 2007-04-19 2008-11-06 Bussan Food Science Kk Method for improving activity of reactive oxygen species-scavenging enzyme group
US11541080B2 (en) 2010-08-04 2023-01-03 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10617724B2 (en) 2010-08-04 2020-04-14 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en) 2010-08-04 2018-07-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en) 2010-08-04 2023-12-26 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en) 2010-08-04 2018-09-04 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en) 2010-08-04 2020-12-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en) 2010-08-04 2022-11-22 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en) 2010-08-04 2022-11-08 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en) 2010-08-04 2021-12-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en) 2010-08-04 2019-05-07 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11173183B2 (en) 2010-08-04 2021-11-16 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en) 2010-08-04 2021-09-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en) 2010-08-04 2019-06-25 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en) 2010-08-04 2021-04-27 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en) 2010-08-04 2019-11-05 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en) 2010-08-04 2021-08-31 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en) 2010-08-04 2020-04-07 Crestovo Holdings, Inc. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en) 2010-08-04 2020-06-09 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9308226B2 (en) 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en) 2010-08-04 2021-07-20 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10849937B2 (en) 2010-08-04 2020-12-01 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10251914B2 (en) 2011-03-09 2019-04-09 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US11801269B2 (en) 2011-03-09 2023-10-31 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US10286012B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US12295974B2 (en) 2011-03-09 2025-05-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286011B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10028980B2 (en) 2011-03-09 2018-07-24 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US12084727B2 (en) 2012-05-25 2024-09-10 Arizona Board Of Regents On Behalf Of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en) 2015-05-14 2021-09-21 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US12161678B2 (en) 2015-05-14 2024-12-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US10821138B2 (en) 2015-05-14 2020-11-03 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US12186349B2 (en) 2016-07-01 2025-01-07 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10561690B2 (en) 2016-08-03 2020-02-18 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11071759B2 (en) 2016-08-03 2021-07-27 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US12390496B2 (en) 2016-08-03 2025-08-19 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11529375B2 (en) 2017-04-05 2022-12-20 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US12285447B2 (en) 2018-07-13 2025-04-29 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
JP3850891B2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
JPH07242539A (en) Composition having laxative effect
US5219573A (en) L-sugar laxatives
KR100872681B1 (en) Arthritis Treatment
US10449165B2 (en) Foods, systems, methods, and kits for providing electrolyte replacement
US20080044493A1 (en) Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer
JPH05255097A (en) Liquid composition
JP2002125638A (en) Joint strengthening beverage
US5137716A (en) Method of reducing weight in mammals
JPWO2008053984A1 (en) Health food containing aloe and agar
US20070259094A1 (en) N-acetylglucosamine as a food and beverage additive
EP1175906B1 (en) Blood flow improvers and thrombosis preventives or remedies comprising glucosamine
CA2408023C (en) Glucosamine as a food and beverage additive
JPH09505824A (en) Use of dimethicone in the treatment of constipation
SMITH et al. The diet in the treatment of cardiac failure
JPH0995448A (en) Method for increasing blood biotin concentration and biotin-containing food and drink
Brucker Management of common minor discomforts in pregnancy: Part III: Managing gastrointestinal problems in pregnancy
WO2003000299A1 (en) Laxative preparation
PL178817B1 (en) Low calorie purgative jelly on the basis of liquid paraffin and lactulose and method of obtaining same
WO1993018756A1 (en) Anion exchange resin compositions
Abt Injuries produced by starch
AU2002312652B2 (en) Laxative preparation
JPS61289043A (en) Drug, food and drink having remedying effect on diseases of gynecologic system
Stebbins et al. Clinical use of cholestyramine resin in diarrheas of various etiology
US20200360423A1 (en) Solid concentrated constipation treatment formulations
AU2002312652A1 (en) Laxative preparation

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Effective date: 20050531

Free format text: JAPANESE INTERMEDIATE CODE: A131

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050801

A02 Decision of refusal

Effective date: 20060516

Free format text: JAPANESE INTERMEDIATE CODE: A02

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060608

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Effective date: 20060712

Free format text: JAPANESE INTERMEDIATE CODE: A911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Effective date: 20060815

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060831

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 3

Free format text: PAYMENT UNTIL: 20090908

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090908

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090908

Year of fee payment: 3

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 4

Free format text: PAYMENT UNTIL: 20100908

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 4

Free format text: PAYMENT UNTIL: 20100908

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 5

Free format text: PAYMENT UNTIL: 20110908

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120908

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees